Youngene Therapeutics Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, metabolic syndrome, stroke, metabolic dysfunction-associated steatohepatitis, cardiovascular and renal disorders, among others.
Primary aldosteronism (PA), caused by bilateral adrenal hyperplasia or aldosteronomas, is the leading cause of endocrine hypertension, with an estimated prevalence of 10%-20% in patients in tertiary hospitals.
Setonix Pharmaceuticals has described peroxisome proliferator-activated receptor γ (PPARγ) modulators reported to be useful for the treatment of inflammatory disorders, metabolic syndrome, obesity, viral infection, cancer, lipid metabolism and glucose metabolism disorders.
Researchers from Congruence Therapeutics Inc. have described the development of a mouse model of genetic obesity with a clinically relevant, naturally occurring human melanocortin MC4 receptor (MC4R) mutation.
Researchers from Adipo Therapeutics LLC presented data from preclinical studies that aimed to assess the γ-secretase inhibitor ADPO-002 (dibenzazepine) for the treatment of obesity.
Researchers at Harvard Medical School have found that blocking the neuron-released peptide CGRP decreases pain sensitivity and reduces lesion size in endometriosis. Endometriosis is a painful, steroid-dependent inflammatory condition in which tissue similar to that of the endometrial lining grows and establishes outside the uterine mucosa.
Gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity have been disclosed in a Pfizer Inc. patent.
Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).
RSS
